全文获取类型
收费全文 | 77944篇 |
免费 | 40824篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 1504篇 |
儿科学 | 4261篇 |
妇产科学 | 552篇 |
基础医学 | 15529篇 |
口腔科学 | 5283篇 |
临床医学 | 12339篇 |
内科学 | 23033篇 |
皮肤病学 | 7453篇 |
神经病学 | 13277篇 |
特种医学 | 2230篇 |
外科学 | 13975篇 |
综合类 | 27篇 |
一般理论 | 23篇 |
预防医学 | 4368篇 |
眼科学 | 1237篇 |
药学 | 5725篇 |
中国医学 | 1009篇 |
肿瘤学 | 6967篇 |
出版年
2023年 | 25篇 |
2022年 | 34篇 |
2021年 | 1265篇 |
2020年 | 5038篇 |
2019年 | 10805篇 |
2018年 | 10067篇 |
2017年 | 11429篇 |
2016年 | 12076篇 |
2015年 | 11908篇 |
2014年 | 11810篇 |
2013年 | 12338篇 |
2012年 | 4085篇 |
2011年 | 4029篇 |
2010年 | 8901篇 |
2009年 | 5249篇 |
2008年 | 2081篇 |
2007年 | 963篇 |
2006年 | 1003篇 |
2005年 | 780篇 |
2004年 | 787篇 |
2003年 | 806篇 |
2002年 | 890篇 |
2001年 | 786篇 |
2000年 | 698篇 |
1999年 | 295篇 |
1998年 | 69篇 |
1997年 | 57篇 |
1996年 | 54篇 |
1995年 | 32篇 |
1994年 | 39篇 |
1993年 | 35篇 |
1992年 | 36篇 |
1991年 | 29篇 |
1990年 | 25篇 |
1989年 | 17篇 |
1988年 | 18篇 |
1987年 | 14篇 |
1986年 | 14篇 |
1985年 | 22篇 |
1984年 | 20篇 |
1983年 | 16篇 |
1982年 | 22篇 |
1981年 | 24篇 |
1980年 | 14篇 |
1979年 | 10篇 |
1978年 | 13篇 |
1976年 | 9篇 |
1974年 | 6篇 |
1971年 | 7篇 |
1970年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 9 毫秒
991.
992.
Vladimir Carli Peter Parzer Camilla Wasserman Birgitta Floderus Alan Apter Judit Balazs Shira Barzilay Julio Bobes Romuald Brunner Paul Corcoran Doina Cosman Padraig Cotter Romain Despalins Nadja Graber Francis Guillemin Christian Haring Jean‐Pierre Kahn Laura Mandelli Dragan Marusic Gergely Mészáros George J. Musa Vita Postuvan Franz Resch Pilar A. Saiz Merike Sisask Airi Varnik Marco Sarchiapone Christina W. Hoven Danuta Wasserman 《Addiction (Abingdon, England)》2012,107(12):2210-2222
993.
Risk of Active Tuberculosis among Index Case of Householders—A Long‐Term Assessment after the Conventional Contacts Study 下载免费PDF全文
994.
995.
996.
997.
998.
999.
Long‐term analysis of phase II studies of single‐agent lenalidomide in relapsed/refractory mantle cell lymphoma 下载免费PDF全文
Thomas E. Witzig Pier Luigi Zinzani Thomas M. Habermann Joseph M. Tuscano Johannes Drach Radhakrishnan Ramchandren Sevgi Kalayoglu Besisik Kenichi Takeshita Marie‐Laure Casadebaig Bravo Lei Zhang Tommy Fu Andre Goy 《American journal of hematology》2017,92(10):E575-E583
Mantle cell lymphoma (MCL) is a type of non‐Hodgkin lymphoma (NHL) with aggressive disease characteristics resulting in multiple relapses after initial treatment. Lenalidomide is an immunomodulatory agent approved in the US for patients with relapsed/refractory MCL following bortezomib based on results from 3 multicenter phase II studies (2 including relapsed/refractory aggressive NHL and 1 focusing on MCL post‐bortezomib). The purpose of this report is to provide longer follow‐up on the MCL‐001 study (follow‐ups were 6.8 [NHL‐002], 7.6 [NHL‐003], and 52.2 [MCL‐001] months). The 206 relapsed MCL patients treated with single‐agent lenalidomide (25 mg/day PO, days 1 to 21 every 28‐days) had a median age of 67 years (63% ≥65 years), 91% with stage III/IV disease, and 50% with ≥4 previous treatment regimens. With a median follow‐up of X, the combined best overall response rate (ORR) was 33% (including 11% with complete remission [CR]/CR unconfirmed CRu). Lenalidomide produced rapid and durable responses with a median time to response of 2.2 months and median duration of response (DOR) of 16.6 months (95% CI: 11.1%‐29.8%). The safety profile was consistent and manageable; myelosuppression was the most common adverse event (AE). Overall, single‐agent lenalidomide showed consistent efficacy and safety in multiple phase II studies of heavily pretreated patients with relapsed/refractory MCL, including those previously treated with bortezomib. 相似文献
1000.
Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF‐1α‐VEGF pathway in oxygen‐induced retinopathy mice 下载免费PDF全文
Yue Xu Xi Lu Yaguang Hu Boyu Yang Ching‐Kit Tsui Shanshan Yu Lin Lu Xiaoling Liang 《Journal of pineal research》2018,64(4)
Retinopathy of prematurity (ROP) is a retinopathy characterized by retinal neovascularization (RNV) occurring in preterm infants treated with high concentrations of oxygen and may lead to blindness in severe cases. Currently, anti‐VEGF therapy is a major treatment for ROP, but it is costly and may cause serious complications. The previous study has demonstrated that melatonin exerted neuroprotective effect against retinal ganglion cell death induced by hypoxia in neonatal rats. However, whether melatonin is anti‐angiogenic and neuroglial protective in the progression of ROP remains unknown. Thus, this study was to investigate the effect of melatonin on RNV and neuroglia in the retina of oxygen‐induced retinopathy (OIR) mice. The results showed a reduction in retinal vascular leakage in OIR mice after melatonin treatment. Besides, the size of retinal neovascular and avascular areas, the number of preretinal neovascular cell nuclei, and the number of proliferative vascular endothelial cells within the neovascular area were significantly decreased in mice treated with melatonin. After oxygen‐induced injury, the density of astrocytes was decreased, accompanied by morphologic and functional changes of astrocytes. Besides, retinal microglia were also activated. Meanwhile, the levels of inflammatory factors were elevated. However, these pathologic processes were all hindered by melatonin treatment. Furthermore, HIF‐1α‐VEGF pathway was activated in the retina of OIR mice, yet was suppressed in melatonin‐treated OIR mice retinas. In conclusion, melatonin prevented pathologic neovascularization, protected neuroglial cells, and exerts anti‐inflammation effect via inhibition of HIF‐1α‐VEGF pathway in OIR retinas, suggesting that melatonin could be a promising therapeutic agent for ROP. 相似文献